{"title":"用一种药物同时抑制表皮生长因子受体和 PI3K。","authors":"Meghri Katerji, Maxine R. Rubin, John Brognard","doi":"10.1038/s43018-024-00806-0","DOIUrl":null,"url":null,"abstract":"Precision medicine holds immense promise for treating individuals with cancer. A new study unveils MTX-531 — a drug that can inhibit two signaling proteins, EGFR and PI3K — which was developed through innovative computational drug design and offers new hope for more-effective and better-tolerated cancer treatments.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"5 8","pages":"1131-1133"},"PeriodicalIF":23.5000,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dual inhibition of EGFR and PI3K with a single drug\",\"authors\":\"Meghri Katerji, Maxine R. Rubin, John Brognard\",\"doi\":\"10.1038/s43018-024-00806-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Precision medicine holds immense promise for treating individuals with cancer. A new study unveils MTX-531 — a drug that can inhibit two signaling proteins, EGFR and PI3K — which was developed through innovative computational drug design and offers new hope for more-effective and better-tolerated cancer treatments.\",\"PeriodicalId\":18885,\"journal\":{\"name\":\"Nature cancer\",\"volume\":\"5 8\",\"pages\":\"1131-1133\"},\"PeriodicalIF\":23.5000,\"publicationDate\":\"2024-08-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s43018-024-00806-0\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature cancer","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s43018-024-00806-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Dual inhibition of EGFR and PI3K with a single drug
Precision medicine holds immense promise for treating individuals with cancer. A new study unveils MTX-531 — a drug that can inhibit two signaling proteins, EGFR and PI3K — which was developed through innovative computational drug design and offers new hope for more-effective and better-tolerated cancer treatments.
期刊介绍:
Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates.
Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale.
In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.